The Relationship between Plasma ADAMTS13 Levels and Clinical Prognosis in Heart Failure Patients with Type 2 Diabetes Mellitus
10.12259/j.issn.2095-610X.S20250713
- VernacularTitle:血浆ADAMTS13水平与心力衰竭合并2型糖尿病患者临床预后的关系
- Author:
Zhenzhen LIU
1
;
Ying ZHANG
;
Xinyu GAO
Author Information
1. 西安交通大学第一附属医院榆林医院心血管内科,陕西 榆林 719000
- Keywords:
A disintegrin-like and metalloprotease with thrombospondin type 1 repeats-13;
Heart failure;
Type 2 diabetes mellitus;
Prognosis
- From:
Journal of Kunming Medical University
2025;46(7):110-117
- CountryChina
- Language:Chinese
-
Abstract:
objective To investigate the prognostic value of plasma ADAMTS13 in patients with heart failure complicated with type 2 diabetes mellitus(T2DM).Methods Clinical data were collected from adult patients with acute decompensated heart failure admitted to the Second People's Hospital of Yulin City from January 2019 to December 2020,with a total of 278 cases included.The level of ADAMTS13 was measured using an ELISA kit,and patients were divided into three groups based on the third quartile of ADAMTS13:T1<9.9 μg/L group(n=92),T2≥10.0-18.5 μg/L group(n=93),and T3≥18.5 μg/L group(n=93).The primary outcome was defined as the composite end point of all-cause mortality's or heart failure readmission.Secondary outcomes included all-cause mortality and heart failure readmission.Results Compared with the patients in the highest third quartile of ADAMTS13,the number of T2DM cases,body mass index,uric acid,fasting blood glucose,HbA1c and hs-CRP levels in the patients with the lowest third quartile of ADAMTS13 increased significantly(P<0.05).The absolute risks of main outcome,all-cause death and hospitalization of heart failure were higher in T2DM patients than in non-T2DM patients(χ2=12.028,8.725,9.023,all P=0.000).The differences in heart failure rate among patients with different ADAMTS13 levels were statistically significant(χ2=9.384,P=0.002).Every doubling of ADAMTS13 was related to a decreased risk of the main outcomes in HF patients with T2DM(HR=0.69,95%CI=0.61～0.79),all-cause mortality(HR=0.59,95%CI=0.47～0.74)and heart failure readmission(HR=0.75,95%CI=0.65～0.87).Conclusion ADAMTS13 is an independent biomarker for risk stratification in HF,especially in patients with T2DM.
